Reviva Pharmaceuticals Holdings, Inc.
NCM: RVPHLive Quote
📈 ZcoreAI Score
Our AI model analyzes Reviva Pharmaceuticals Holdings, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get RVPH Z-Score →About Reviva Pharmaceuticals Holdings, Inc.
Healthcare
Biotechnology
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
📊 Fundamental Analysis
Reviva Pharmaceuticals Holdings, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -420.0%, which indicates that capital utilization is currently under pressure.
At a current price of $0.77, RVPH currently trades near the bottom of its 52-week range (1%), indicating potential value or weakness (Range: $0.59 - $23.20).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$9.88M
Trailing P/E
--
Forward P/E
-0.93
Beta (5Y)
0.64
52W High
$23.20
52W Low
$0.59
Avg Volume
503K
Day High
Day Low